In conjunction with the STP, the BSTP have organised the following webinar:
Presenter: Tracey L. Papenfuss, DVM, PhD (Immunology), DACVP
Title: Immuno-oncology, checkpoint inhibitors and beyond
Date: July 12, 2018
Time: 12:00 (noon) EST (17.00 UK time)
To register, visit:
Abstract: Modulating the immune system to prevent and treat disease is complex. Significant advances on how we can selectively and very specifically modulate immune responses provides exciting opportunities to treat a variety of disease states. Perhaps in no other disease, has there been as much excitement, or ability to fine tune immune responses than in cancer. In the disease state of cancer, the immune system is dysregulated, dysfunctional, and fails to remove tumor cells. Immuno-oncology (or cancer immunotherapy) is the study of and approach to use the body’s own immune system to help fight cancer. Significant advancements in the development of numerous cancer immunotherapies utilizing various modalities has triggered an explosion of research into new models and tools. This webinar will discuss the various aspects of immune dysregulation that occurs during cancer and therapeutic approaches to combat this dysregulation and restore anti-tumor responses. The mechanisms and application of new therapies, including checkpoint inhibitors, will be discussed.
Speaker Bio: Dr. Tracey L. Papenfuss is a Principal Pathologist and Immunotoxicology Scientific Advisor at MPI Research, A Charles River Company, where she provides expertise and consultation in immunology, immunopathology and immunotoxicology in preclinical drug development and safety assessment to assess how novel therapies impact the immune system.
Dr. Papenfuss obtained her D.V.M. and M.S. from the University of Minnesota and Ph.D. from The Ohio State University working on innate-adaptive immune responses and immune regulation. She went on to establish and direct an early research and discovery immunotherapeutics and immunopathology laboratory at The Ohio State University working on cancer immunology, autoimmunity and inflammatory diseases. In 2014, she took a position as a Pathologist in preclinical safety assessment at WIL Research Laboratories (now Charles River Laboratories) until moving to her current position as Immunotoxicology Scientific Advisor and Principal Pathologist in 2017. She has more than 15 years of specialized experience and is the author/co-author of over 35 peer-reviewed articles and 10 book chapters.